CD8A and neoplasm: Figure 2b–g shows multi-colour flow cytometric analysis of tumour-infiltrating lymphocytes in 4T1.2 tumour-bearing mice with or without treatment of PEG2k-Fmoc-NLG(L). It is clear that more CD4+ and CD8+ T cells were found in the tumours that received the treatment of PEG2k-Fmoc-NLG(L). In addition, the number of regulatory T cells (Tregs) was significantly reduced in the tumours treated with PEG2k-Fmoc-NLG(L).